Express Consent. By checking the consent checkbox and providing your mobile phone number, you affirm that you are a US resident, 18 years of age or older, and expressly consent to receive non-marketing and marketing text messages (SMS) and texts with images (MMS) from Dermavant Sciences, Inc. (“DERMAVANT”) or its partners in connection with the VIP Updates program (“PROGRAM”). You understand that your consent to receive text messages is not required for the receipt of goods or services from DERMAVANT. These messages may be sent from Short code: 32504.
Message Frequency Varies.
Cost.DERMAVANT encourages you to check with your mobile service provider to see what message and data rates may apply, including any applicable roaming charges.
Opt In. Opt-in by web form at https://vtama.com.
Opt Out. You may opt out of receiving all mobile messages relating to the PROGRAM at any time by replying “STOP,” or texting “STOP” to 32504. Please note that mobile and email opt outs are separate processes and that one does not affect the other.
Support. For assistance reply to any PROGRAM text with “HELP”, text “HELP” to 32504, or email vipupdates@dermavant.com.
Eligibility. To receive text messages from the PROGRAM, you must be a resident of the US, and 18 years of age or older, and have a phone with messaging capabilities with the Major or Minor Carriers noted above.
Your Mobile Telephone Number. You represent that you are the account holder for the mobile telephone number you opt-in to receive text messages for the PROGRAM.
Access or Delivery to Mobile Network is Not Guaranteed. Delivery of information and content to a mobile device is not guaranteed and may fail to due to a variety of circumstances or conditions. Alerts sent via text message may not be delivered if the mobile phone is not in range of a transmission site, or if sufficient network capacity is not available at a particular time. Even within a coverage area, factors beyond the control of the wireless carrier may interfere with message delivery, including the customer's equipment, terrain, proximity to buildings, foliage, and weather. DERMAVANT will not be held responsible for any delays in or failure of the receipt of any text messages as delivery is subject to effective transmission from your mobile service provider or network operator. You understand and acknowledge that network services, including but not limited to mobile network services, are outside of DERMAVANT’s control, and DERMAVANT is not responsible or liable for issues arising from them.
Privacy. DERMAVANT understands and values the importance of your privacy. Please be aware that the data obtained from you in connection with this SMS message service may, among other things, include your name, cell phone number, carrier name, and message date, time, and content. We may use this information to contact you and to provide the services you request from us. For more information on how we collect and use your data, please read our Privacy Policy at https://dermavant.com/privacy-policy/.
You understand that a significant portion of the PROGRAM is conducted via text messaging. These text messages may contain health information. Standard text messaging is not encrypted, and a third party could read these messages.
PROGRAM Terms of Use. You understand that this program is not a means to communicate product issues or negative side effects to DERMAVANT. You are encouraged to report negative side effects of prescription drugs to the FDA at www.fda.gov/medwatch, or by phone at 1-800-FDA-1088. DERMAVANT is not responsible for monitoring or recording text messages that may constitute an issue or negative side effect. For additional information about your medication, please call DERMAVANT at 1-8-DERMAVANT (1-833-762-8268) Monday through Friday, 8:00 AM – 8:00 PM ET.
NOT MEDICAL ADVICE. The PROGRAM includes text messages with tips and support. Our content and communications are not intended to be a replacement or substitute for professional medical advice. The content and communications do not constitute medical advice, diagnosis, or treatment. You acknowledge and understand that you will seek the advice of a physician or other qualified health care provider with any questions that arise regarding any medical condition. You acknowledge that all information and guidance provided by you is solely at your own risk.
Changes to Terms of Use. DERMAVANT may revise, modify, or amend the PROGRAM’s Mobile Terms of Use at any time. Any such revision, modification, or amendment will take effect when such changes are circulated to PROGRAM participants via text message.
Termination of Text Messaging. DERMAVANT may suspend or terminate your receipt of PROGRAM text messages if DERMAVANT believes you are in breach of these Mobile Terms of Use. Your receipt of PROGRAM text messages is also subject to termination in the event that your mobile telephone service terminates or lapses. DERMAVANT reserves the right to modify or discontinue, temporarily or permanently, all or any part of PROGRAM text messages, with or without notice. You assume sole responsibility for the proper use and scheduling of any medications, treatments, and procedures related to the patient's health care and disease management. DERMAVANT assumes no responsibility for the accuracy or appropriateness of any information entered by you.
IMPORTANT SAFETY INFORMATION
Indications: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for:
the topical treatment of plaque psoriasis in adults.
the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.
Adverse Events: In plaque psoriasis, the most common adverse reactions (incidence ≥1%) were: red raised bumps around the hair pores (folliculitis), pain or swelling in the nose and throat (nasopharyngitis), skin rash or irritation, including itching and redness, peeling, burning, or stinging (contact dermatitis), headache, itching (pruritus), and flu (influenza).
Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, red raised bumps around the hair pores (folliculitis), lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and stomach-area (abdominal) pain.
